Sanofi said on Tuesday it had stopped supplying Praluent, a popular cholesterol drug jointly developed by the French ...

Sanofi (SNY) halts shipments of cholesterol drug Praluent developed with Regeneron (REGN) due to availability issues. Read ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict ...

Response Pharmaceuticals’ drug has helped reduce the amount of weight a patient regains after treatment with glucagon-like ...

Sanofi has initiated a Phase 2a clinical study titled A Parallel-group Treatment, Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Umbrella Study to Evaluate th ...

The outcome of this study could significantly impact Sanofi’s stock performance and investor sentiment, as successful results may enhance their competitive edge in the multiple sclerosis treatment ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs ...

Arguably the FDA’s most anticipated decision this month is for a subcutaneous induction formulation of Biogen and Eisai’s ...

OverviewIn 2025, data science offers lucrative roles across technology, finance, healthcare, and retail.Top careers include ...

Families who have never shared their stories publicly before are speaking out following a series of special reports on ITV ...

THE Court of Appeals has reaffirmed its previous decision favoring the ruling of the Quezon City Regional Trial Court that ...